Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Weekly News Recap #Phispers
1. Dcc-3014
2. 1628606-05-2
3. Vimseltinib [inn]
4. Vimseltinib [usan]
5. Px9ftm69bf
6. Dcc3014
7. 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3h)-one
8. 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one
9. Dp-6865
10. 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3h)-pyrimidinone
11. 4(3h)-pyrimidinone, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-
12. Unii-px9ftm69bf
13. Vimseltinib [who-dd]
14. Schembl16047448
15. Gtpl11190
16. Ex-a4700
17. Nsc828316
18. Who 11443
19. Nsc-828316
20. Example 10 [wo2014145025a2]
21. Hy-136256
22. Cs-0121044
23. 3-methyl-5-(6-methyl-5-{[2-(1-methyl-1h-pyrazol-4-yl)pyridin-4-yl]oxy}pyridin-2-yl)-2-[(propan-2-yl)amino]pyrimidin-4(3h)-one
24. Z6v
Molecular Weight | 431.5 g/mol |
---|---|
Molecular Formula | C23H25N7O2 |
XLogP3 | 1.5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Exact Mass | 431.20697307 g/mol |
Monoisotopic Mass | 431.20697307 g/mol |
Topological Polar Surface Area | 97.5 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 740 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
Romvimza (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: Romvimza
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2025
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Full Approval for Deciphera’s ROMVIMZA™ in Treating TGCT
Details : Romvimza (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.
Product Name : Romvimza
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2025
Details:
DCC-3014 (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 15, 2024
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts Deciphera’s NDA for Vimseltinib to Treat Tenosynovial Giant Cell Tumor
Details : DCC-3014 (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.
Product Name : DCC-3014
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 15, 2024
Details:
DCC-3014 (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 18, 2024
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EMA Accepts Deciphera’s MAA for Vimseltinib for Tenosynovial Giant Cell Tumor
Details : DCC-3014 (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.
Product Name : DCC-3014
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 18, 2024
Details:
DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 30, 2023
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.
Product Name : DCC-3014
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2023
Details:
Deciphera intends to use the proceeds to fund its planned Phase 3 INSIGHT study of QINLOCK versus sunitinib, to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: J.P. Morgan
Deal Size: $143.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 24, 2023
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $143.7 million
Deal Type : Public Offering
Details : Deciphera intends to use the proceeds to fund its planned Phase 3 INSIGHT study of QINLOCK versus sunitinib, to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tum...
Product Name : DCC-3014
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 24, 2023
Details:
Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: J.P. Morgan
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 19, 2023
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $125.0 million
Deal Type : Public Offering
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Details : Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.
Product Name : DCC-3014
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 19, 2023
Details:
Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: J.P. Morgan
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 18, 2023
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $125.0 million
Deal Type : Public Offering
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Details : Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.
Product Name : DCC-3014
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 18, 2023
Details:
DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 03, 2023
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.
Product Name : DCC-3014
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2023
Details:
Updated Results for DCC-3014 (vimseltinib) Showed Objective Response Rate of 69% in Phase 1, 53% in Phase 2 Cohort A, and 46% in Phase 2 Cohort B; Demonstrated a Clinical Benefit Rate of 100% Across All Phase 1/2 Patients.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 09, 2022
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Updated Results for DCC-3014 (vimseltinib) Showed Objective Response Rate of 69% in Phase 1, 53% in Phase 2 Cohort A, and 46% in Phase 2 Cohort B; Demonstrated a Clinical Benefit Rate of 100% Across All Phase 1/2 Patients.
Product Name : DCC-3014
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2022
Details:
Deciphera intends to use the net proceeds from the offering to continue to fund the development of vimseltinib including in its pivotal Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway, additional clinical trials.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: J.P. Morgan
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 29, 2022
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $172.5 million
Deal Type : Public Offering
Details : Deciphera intends to use the net proceeds from the offering to continue to fund the development of vimseltinib including in its pivotal Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway, additional clinical ...
Product Name : DCC-3014
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 29, 2022
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
87
PharmaCompass offers a list of Vimseltinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vimseltinib manufacturer or Vimseltinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vimseltinib manufacturer or Vimseltinib supplier.
PharmaCompass also assists you with knowing the Vimseltinib API Price utilized in the formulation of products. Vimseltinib API Price is not always fixed or binding as the Vimseltinib Price is obtained through a variety of data sources. The Vimseltinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Vimseltinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vimseltinib, including repackagers and relabelers. The FDA regulates Vimseltinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vimseltinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Vimseltinib supplier is an individual or a company that provides Vimseltinib active pharmaceutical ingredient (API) or Vimseltinib finished formulations upon request. The Vimseltinib suppliers may include Vimseltinib API manufacturers, exporters, distributors and traders.
Vimseltinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vimseltinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vimseltinib GMP manufacturer or Vimseltinib GMP API supplier for your needs.
A Vimseltinib CoA (Certificate of Analysis) is a formal document that attests to Vimseltinib's compliance with Vimseltinib specifications and serves as a tool for batch-level quality control.
Vimseltinib CoA mostly includes findings from lab analyses of a specific batch. For each Vimseltinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vimseltinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Vimseltinib EP), Vimseltinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vimseltinib USP).